{"id":"https://openalex.org/W4361951007","doi":"https://doi.org/10.1158/1078-0432.c.6522158.v1","title":"Data from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer","display_name":"Data from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361951007","doi":"https://doi.org/10.1158/1078-0432.c.6522158.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6522158.v1","doi":"https://doi.org/10.1158/1078-0432.c.6522158.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6522158.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"parent_works":[],"lineage":["https://openalex.org/W4361951007"],"child_works_count":0,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6522158.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001814176","display_name":"Fabrice Andr\u00e9","orcid":"https://orcid.org/0000-0001-5795-8357","observed_orcids":["https://orcid.org/0000-0001-5795-8357","https://orcid.org/0000-0002-6272-6048"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fabrice Andr\u00e9","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041410352","display_name":"Thomas Bachelot","orcid":"https://orcid.org/0000-0002-0866-9484","observed_orcids":["https://orcid.org/0000-0002-0866-9484"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas Bachelot","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071553983","display_name":"Mario Campone","orcid":"https://orcid.org/0000-0002-5196-5908","observed_orcids":["https://orcid.org/0000-0002-5196-5908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mario Campone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058791215","display_name":"Florence Dalenc","orcid":"https://orcid.org/0000-0002-9854-4182","observed_orcids":["https://orcid.org/0000-0002-9854-4182"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Florence Dalenc","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090108117","display_name":"Jos\u00e9 Manuel P\u00e9rez-Garc\u00eda","orcid":"https://orcid.org/0000-0003-4238-2046","observed_orcids":["https://orcid.org/0000-0003-4238-2046","https://orcid.org/0009-0004-2204-2014"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jose M. Perez-Garcia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060044961","display_name":"Nicholas C. Turner","orcid":"https://orcid.org/0000-0001-8937-0873","observed_orcids":["https://orcid.org/0000-0001-8937-0873"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicholas Turner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hope Rugo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103080396","display_name":"John Smith","orcid":"https://orcid.org/0000-0002-2097-8757","observed_orcids":["https://orcid.org/0000-0002-2097-8757"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John W. Smith","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037790221","display_name":"St\u00e9phanie Deudon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephanie Deudon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113700678","display_name":"Michael M. Shi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Shi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100419804","display_name":"Yong Zhang","orcid":"https://orcid.org/0000-0002-6072-0697","observed_orcids":["https://orcid.org/0000-0002-6072-0697"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yong Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113455755","display_name":"Andrea Kay","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrea Kay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066646841","display_name":"Diana Graus Porta","orcid":"https://orcid.org/0009-0007-0972-3896","observed_orcids":["https://orcid.org/0009-0007-0972-3896"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diana Graus Porta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021409571","display_name":"Alejandro Javier Yovine","orcid":"https://orcid.org/0000-0001-7664-0192","observed_orcids":["https://orcid.org/0000-0001-7664-0192"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alejandro Yovine","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jos\u00e9 Baselga","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dovitinib","display_name":"dovitinib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/fgfr1-amplification","display_name":"FGFR1 amplification","score":0.8600000143051147},{"id":"https://openalex.org/keywords/fgfr2-amplification","display_name":"FGFR2 amplification","score":0.984000027179718},{"id":"https://openalex.org/keywords/fgfr3-amplification","display_name":"FGFR3 amplification","score":0.8240000009536743},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.6470000147819519},{"id":"https://openalex.org/keywords/fgfr-tyrosine-kinase-inhibitors","display_name":"FGFR tyrosine kinase inhibitors","score":0.765999972820282},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8080000281333923},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.8410000205039978},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7110000252723694},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.628000020980835},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7239999771118164}],"concepts":[{"id":"https://openalex.org/C49418065","wikidata":"https://www.wikidata.org/wiki/Q14914258","display_name":"Fibroblast growth factor receptor 1","level":4,"score":0.5614970922470093},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5318673849105835},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.529615044593811},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.44678086042404175},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4296553432941437},{"id":"https://openalex.org/C74373430","wikidata":"https://www.wikidata.org/wiki/Q24727126","display_name":"Fibroblast growth factor","level":3,"score":0.41724807024002075},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.37621772289276123},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3455091118812561}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6522158.v1","doi":"https://doi.org/10.1158/1078-0432.c.6522158.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6522158.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6522158.v1","doi":"https://doi.org/10.1158/1078-0432.c.6522158.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6522158.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2098320019","https://openalex.org/W2245460722","https://openalex.org/W2590650442","https://openalex.org/W2560839005","https://openalex.org/W2323285511","https://openalex.org/W2587095588","https://openalex.org/W1986838201","https://openalex.org/W2603379995","https://openalex.org/W1983382702","https://openalex.org/W1997454429"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"Fibroblast":[2],"growth":[3,143],"factor":[4],"receptor":[5,82,95],"1":[6,172],"(FGFR1)":[7],"and":[8,19,35,58,93,116,130,171,177,236],"FGFR2":[9],"amplifications":[10,118,183],"are":[11,20],"observed":[12,167],"in":[13,40,52,68,104,128,144,153,168,184,198,204,214,230,240],"approximately":[14],"10%":[15],"of":[16,32,48,77,90,113],"breast":[17,42,54,85,135,146,179,196,223,232,241],"cancers":[18,242],"related":[21],"to":[22,191],"poor":[23],"outcomes.":[24],"We":[25],"evaluated":[26,51,67],"whether":[27],"dovitinib":[28,49],"(TKI258),":[29],"an":[30,59,193],"inhibitor":[31],"FGFR1,":[33,114,185],"FGFR2,":[34,115,186],"FGFR3,":[36],"presented":[37],"antitumor":[38,228],"activity":[39,47,229,239],"FGFR-amplified":[41,231],"cancers.":[43],"Experimental":[44],"Design:":[45],"Preclinical":[46],"was":[50,65,100,166,207],"both":[53],"cancer":[55,86,136,147,197,233],"cell":[56,137,234],"lines":[57,235],"FGFR1-amplified":[60,145],"xenograft":[61],"model":[62],"(HBCx2).":[63],"Dovitinib":[64,124,139,226],"then":[66],"a":[69,211],"phase":[70],"II":[71],"trial":[72],"that":[73],"included":[74],"4":[75],"groups":[76],"patients":[78,150,215],"with":[79,175,210,220,243],"human":[80],"EGF":[81],"2\u2013negative":[83],"metastatic":[84],"on":[87],"the":[88,154,201],"basis":[89],"FGFR1":[91,98],"amplification":[92,99],"hormone":[94],"(HR)":[96],"status.":[97],"assessed":[101,110],"by":[102,119],"silver":[103],"situ":[105],"hybridization.":[106],"Preplanned":[107],"retrospective":[108],"analyses":[109],"predictive":[111],"value":[112],"FGF3":[117,188],"quantitative":[120],"PCR":[121],"(qPCR).":[122],"Results:":[123],"monotherapy":[125],"inhibits":[126,141],"proliferation":[127],"FGFR1-":[129],"FGFR2-amplified,":[131],"but":[132],"not":[133,218],"FGFR-normal,":[134],"lines.":[138],"also":[140],"tumor":[142],"xenografts.":[148],"Eighty-one":[149],"were":[151,189],"enrolled":[152],"trial.":[155],"Unconfirmed":[156],"response":[157],"or":[158,187],"stable":[159],"disease":[160],"for":[161],"more":[162],"than":[163],"6":[164],"months":[165],"5":[169],"(25%)":[170],"(3%)":[173],"patient(s)":[174],"FGFR1-amplified/HR-positive":[176],"FGFR1-nonamplified/HR-positive":[178],"cancer.":[180,224],"When":[181],"qPCR-identified":[182],"grouped":[190],"define":[192],"FGF":[194,221,244],"pathway\u2013amplified":[195,222],"HR-positive":[199],"patients,":[200],"mean":[202],"reduction":[203],"target":[205],"lesions":[206],"21.1%":[208],"compared":[209],"12.0%":[212],"increase":[213],"who":[216],"did":[217],"present":[219],"Conclusion:":[225],"showed":[227],"may":[237],"have":[238],"pathway":[245],"amplification.":[246],"Clin":[247],"Cancer":[248],"Res;":[249],"19(13);":[250],"3693\u2013702.":[251],"\u00a92013":[252],"AACR.":[253]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2023-04-05T00:00:00"}